OLDWICK, N.J.–(BUSINESS WIRE)–In this episode of AMBestTV, Myles Gould, director, analytics, and Yuan Tian, senior financial analyst, both of AM Best, said that competition, poor pricing discipline and investments challenge the India non-life market. Click on http://www.ambest.com/v.asp?v=india620 to view the entire program.
MAA is for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B Application based on positive results from TRANSCEND NHL 001 study and additional TRANSCEND WORLD 001 study PRINCETON, N.J.–(BUSINESS
Portal provides faster and easier access to robust product information and insight to product roadmaps and future of insurance technologies MORRISTOWN, N.J.–(BUSINESS WIRE)–Majesco (NASDAQ: MJCO), a global provider of cloud insurance platform software, today announced a new product portal – providing customers
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has removed from under review with developing implications and affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings of “a” of National Lloyds Insurance Company (NLIC) and American Summit Insurance Company (ASIC), collectively
PISCATAWAY, N.J.–(BUSINESS WIRE)–The IEEE-ISTO Printer Working Group (PWG) has released IPP 3D Printing Extensions v1.1 (PWG 5100.21-2019) and PWG Safe G-Code Subset for 3D Printing v1.0 Best Practices (PWG 5199.7-2019). These documents build on previously defined extensions to the Internet Printing Protocol
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating (FSR) of A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” of State Automobile Mutual Insurance Company (State Auto) and its operating subsidiaries. Concurrently, AM Best has affirmed the
Improvement in nonresidential and nonbuilding activity push starts higher NEW JERSEY–(BUSINESS WIRE)–Total construction starts increased 6% in June to a seasonally adjusted annual rate of $641.4 billion. This marks the second consecutive monthly gain in construction starts following the COVID-19 induced declines
Humanigen’s investigational monoclonal antibody, lenzilumab, was developed using Catalent’s proprietary GPEx® cell line development technology Expanded partnership established product supply for lenzilumab, an investigational Phase 3 product for COVID-19 Catalent’s OneBio® integrated biologics suite expected to accelerate development, manufacturing and supply of
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb”) announced today the expiration and final results of its offers to exchange (the “Registered Exchange Offers”) any and all of its outstanding (i) $19,000,000,000 aggregate principal amount of senior unsecured notes previously issued